IRF-2 is over-expressed in pancreatic cancer and promotes the growth of pancreatic cancer cells
IRF-2 is over-expressed in pancreatic cancer and promotes the growth of pancreatic cancer cells
复制标题
DOI：
10.1007/s13277-011-0273-3
复制
发表时间：
2012-02-01
期刊：
影响因子：
--
通讯作者：
Jin, Dayong
中科院分区：
文献类型：
--
作者：
Cui, Lei;Deng, Yuezhen;Jin, Dayong
胰腺癌是世界上恶性程度最高的疾病之一。干扰素调节因子2(IRF-2)是一种干扰素调节因子，已被认为是不同类型癌症的癌基因。在本研究中，我们发现IRF-2在胰腺癌组织中的表达上调，并且与肿瘤的大小、分化程度、肿瘤的转移分期和患者的生存有关。在胰腺癌细胞中，抑制IRF-2的表达抑制了细胞在液体培养和软琼脂上的生长。从机制上讲，IRF-2通过调控细胞增殖和凋亡效应因子，如细胞周期蛋白D1和Bax来调控胰腺癌细胞的生长。综上所述，这些结果提示IRF-2在胰腺癌的发生发展中起重要作用，下调IRF-2的表达有望成为胰腺癌治疗的新靶点。
Pancreatic cancer is one of the most malignant diseases in the world. Interferon regulator factor 2 (IRF-2), an interferon regulatory factor, has been known to act as an oncogene in distinct types of cancer. In this study, we found that the expression of IRF-2 was up-regulated in primary pancreatic cancer samples and associated with tumor size, differentiation, tumor-node-metastasis stage, and survival of the patients. In pancreatic cancer cells, knockdown on the expression of IRF-2 inhibited cell growth in the liquid culture and on the soft agar. Mechanistically, IRF-2 modulated the growth of pancreatic cancer cells through regulating proliferation and apoptosis effectors, such as cyclin D1 and BAX. Collectively, these results suggest that IRF-2 plays an important role in the tumorigenesis of pancreatic cancer and down-regulation of IRF-2 would be a new treatment target for pancreatic cancer.